Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Illumina, Inc.

Frank J Steemers1, Kevin L Gunderson

  • 1Illumina Inc., 9885 Towne Centre Drive, San Diego, CA 92121, USA. Fsteemers@illumina.com

Pharmacogenomics
|October 7, 2005
PubMed
Summary
This summary is machine-generated.

Illumina provides advanced genomics tools, including microarray platforms and proprietary assays, for high-throughput genotyping and gene expression analysis. These solutions enable researchers to scale experiments and reduce costs in large-scale genomics research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atlas-scale single-cell chromatin accessibility using nanowell-based combinatorial indexing.

Genome research·2023
Same author

High-throughput robust single-cell DNA methylation profiling with sciMETv2.

Nature communications·2022
Same author

High-content single-cell combinatorial indexing.

Nature biotechnology·2021
Same author

Spatially mapped single-cell chromatin accessibility.

Nature communications·2021
Same author

A human cell atlas of fetal chromatin accessibility.

Science (New York, N.Y.)·2020
Same author

A human cell atlas of fetal gene expression.

Science (New York, N.Y.)·2020
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Area of Science:

  • Genomics
  • Biotechnology
  • Molecular Biology

Background:

  • Illumina, Inc. is a genomics tool company specializing in integrated array-based systems.
  • The company offers solutions for genotyping, gene expression, and epigenetics.

Purpose of the Study:

  • To detail Illumina's microarray platforms and proprietary assay technologies.
  • To highlight the applications and capabilities of these genomics tools for large-scale research.

Main Methods:

  • Development and marketing of integrated array-based systems and assays.
  • Utilizing microarray platforms like Sentrix Array Matrix and Sentrix BeadChip.
  • Employing proprietary assays including GoldenGate, Infinium, and DASL.

Main Results:

Related Experiment Videos

  • Illumina's platforms feature small feature size (3 microm) and dense packing (over 10 million features/microarray).
  • The systems enable parallel analysis of multiple samples on a single device.
  • Proprietary assays have been successfully used for significant projects like the International HapMap Project.

Conclusions:

  • Illumina's technologies facilitate high-throughput, large-scale genomics research.
  • The company focuses on extending assay applications and developing new products.
  • The goal is to provide cost-effective, high-performance solutions for researchers.